Case-Control Study of the Glycotest™ HCC Panel Vs AFP for the Detection of Early-stage Hepatocellular Carcinoma (NCT03878550)
🩺 Plain-English Summary (8th-Grade Level)
Clinical guidelines (AASLD) recommend the use of abdominal ultrasound (US) for surveillance testing for the early detection of Hepatocellular Carcinoma (HCC). The serum protein biomarker alpha-fetoprotein (AFP) is commonly used to augment US but its use alone is not recommended by clinical guidelines. Despite evidence that HCC surveillance improves early detection and reduces mortality from HCC, current HCC surveillance tests lack sensitivity, leaving a significant proportion of patients to present with late-stage disease. The Glycotest HCC Panel has shown better sensitivity than AFP, which is ineffective for the detection of early-stage HCC. This clinical study seeks to validate the Glycotest HCC Panel using a large multicenter cohort of cases and controls that includes patients diagnosed with early-stage HCC against a background of cirrhosis and cirrhotic patients without HCC (at risk) undergoing an established surveillance protocol.
Who can join: Review the eligibility criteria below.
Location: Cedars- Sinai Medical Center — Los Angeles, California
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- Cedars- Sinai Medical Center — Los Angeles, California
- University of California Los Angeles — Los Angeles, California
- Kaiser Permanente Northern California — San Francisco, California
- University of California- San Francisco — San Francisco, California
- Stanford University School of Medicine — Stanford, California
- University of Florida — Gainesville, Florida
- Miami VA Healthcare System — Miami, Florida
- Northwestern University — Chicago, Illinois
- University of Maryland, Baltimore — Baltimore, Maryland
- University of Michigan — Ann Arbor, Michigan
- Henry Ford Health System — Detroit, Michigan
- Mayo Clinic — Rochester, Minnesota
- NYU Langone Health — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Montefiore Medical Center — The Bronx, New York
- Hospital of the University of Pennsylvania (HUP) — Philadelphia, Pennsylvania
- Baylor Scott & White Research Institute — Dallas, Texas
- The University of Texas Southwestern Medical Center — Dallas, Texas
- Baylor College of Medicine — Houston, Texas
- Hebrew University- Hadassah Medical Center — Jerusalem,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma, Hepatocellular
- Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. — Irvine, California
- Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma — San Antonio, Texas
- National Liver Cancer Screening Trial — Los Angeles, California
- Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma — New Brunswick, New Jersey
- 90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia — New Orleans, Louisiana
Explore by condition: All Carcinoma, Hepatocellular clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.